• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Tourmaline Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/13/25 8:00:44 AM ET
    $TRML
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TRML alert in real time by email
    trml-20250313
    FALSE000182750600018275062025-03-132025-03-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________________

    FORM 8-K
    ___________________________________

    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): March 13, 2025
    ___________________________________

    TOURMALINE BIO, INC.
    (Exact name of registrant as specified in its charter)
    ___________________________________

    Delaware
    (State or other jurisdiction of
    incorporation or organization)
    001-40384
    (Commission
    File Number)
    83-2377352
    (I.R.S. Employer
    Identification No.)
    27 West 24th Street, Suite 702
    New York, NY
    (Address of principal executive offices)
    10010
    (Zip Code)
    Registrant's telephone number, including area code: (646) 481-9832
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    ___________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol
    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per shareTRMLThe Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company    ☒
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02 Results of Operations and Financial Condition.

    On March 13, 2025, Tourmaline Bio, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.

    The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.Description
    99.1
    Press Release dated March 13, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    TOURMALINE BIO, INC.
    Date: March 13, 2025
    By:
    /s/ Ryan Robinson
    Name:
    Ryan Robinson
    Title:
    Chief Financial Officer


    Get the next $TRML alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRML

    DatePrice TargetRatingAnalyst
    4/23/2025$70.00Buy
    Chardan Capital Markets
    3/6/2025$42.00Outperform
    Wedbush
    12/6/2024$50.00Outperform
    BMO Capital Markets
    11/11/2024$48.00 → $49.00Buy
    H.C. Wainwright
    12/15/2023$41.00Buy
    Jefferies
    12/4/2023$48.00Buy
    H.C. Wainwright
    11/17/2023$43.00Buy
    Truist
    10/31/2023$50.00Buy
    Guggenheim
    More analyst ratings

    $TRML
    SEC Filings

    See more
    • Tourmaline Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/20/25 9:02:35 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tourmaline Bio Inc.

      SCHEDULE 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      5/15/25 4:22:00 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Tourmaline Bio Inc.

      10-Q - Tourmaline Bio, Inc. (0001827506) (Filer)

      5/2/25 8:12:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Financials

    Live finance-specific insights

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TRML
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:46:12 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 5:05:20 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tourmaline Bio Inc.

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      11/14/24 4:32:01 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets initiated coverage on Tourmaline with a new price target

      Chardan Capital Markets initiated coverage of Tourmaline with a rating of Buy and set a new price target of $70.00

      4/23/25 8:18:16 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Tourmaline with a new price target

      Wedbush initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $42.00

      3/6/25 7:32:45 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BMO Capital Markets initiated coverage on Tourmaline with a new price target

      BMO Capital Markets initiated coverage of Tourmaline with a rating of Outperform and set a new price target of $50.00

      12/6/24 8:19:37 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

      – Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving >85% hs-CRP reductions from baseline in the 50 mg quarterly arm – – Overall incidence rates of adverse events and serious adverse events in the pacibekitug groups were comparable to placebo through the data extract date – – Results from TRANQUILITY support the advancement of pacibekitug into a potential Phase 3 cardiovas

      5/20/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

      NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor o

      5/19/25 4:05:13 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

      – Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative med

      5/2/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Leadership Updates

    Live Leadership Updates

    See more
    • Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

      NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). "We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of card

      1/10/25 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

      Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa

      4/2/24 7:00:00 AM ET
      $AVTX
      $TRML
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

      NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that Clay Siegall, PhD, has been appointed as Chairman of the Board. "We are absolutely thrilled that Clay has joined Tourmaline as Chairman of the Board," said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. "Clay built Seagen into one of the largest independent biotech companies in the world by taking a therapeutic concept and developing from it multiple successful medicines

      12/14/23 7:30:00 AM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO Kulkarni Sandeep Chidambar

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      2/4/25 4:19:06 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Robinson Ryan F.

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:34 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CBO, GC and Secretary Middlekauff W Bradford

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/29/25 4:23:21 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TRML
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Kulkarni Sandeep Chidambar bought $26,418 worth of shares (1,779 units at $14.85) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/22/24 4:22:14 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO Kulkarni Sandeep Chidambar bought $71,998 worth of shares (5,221 units at $13.79) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      8/20/24 6:09:47 PM ET
      $TRML
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care